Author

Luis Bujanda Fernández de Piérola

KLF5 UPREGULATION IS A COMMON EVENT IN CHOLANGIOCARCINOMA, ACTING AS AN ONCOGENE AND CONSTITUTING A BAD PROGNOSTIC FACTOR
KLF5 UPREGULATION IS A COMMON EVENT IN CHOLANGIOCARCINOMA, ACTING AS AN ONCOGENE AND CONSTITUTING A BAD PROGNOSTIC FACTOR

Luis Bujanda Fernández de Piérola  et al.

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

Luis Bujanda Fernández de Piérola  et al.

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

Luis Bujanda Fernández de Piérola  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Luis Bujanda Fernández de Piérola  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Luis Bujanda Fernández de Piérola  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)
FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

Luis Bujanda Fernández de Piérola  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Luis Bujanda Fernández de Piérola  et al.

Item 21 - 30 / 30
1
2